ArticleAnnals of hematology2025
The heterogeneity of thoracic Castleman disease: implications for classification and personalized management.
Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Castleman disease (CD) is a rare lymphoproliferative disorder categorized into unicentric CD (UCD) and multicentric CD (MCD). Surgical intervention is crucial for both diagnosis and treatment. However, comprehensive comparisons and detailed analyses of surgical outcomes remain limited. We retrospectively reviewed thoracic CD patients treated at our hospital from 2010 to 2024. Clinical, pathological, laboratory, and imaging data were compared between UCD and MCD. Treatment outcomes and prognoses were assessed using multivariate Cox regression. We also compared outcomes between video-assisted thoracoscopic surgery (VATS) and open thoracotomy. Among 88 CD patients, 26.1% were diagnosed with MCD and 73.9% with UCD. MCD patients were significantly older (mean age: 50.1 vs. 40.4, p = 0.002), had a higher male predominance (65.2% vs. 35.4%, p = 0.025), exhibited a greater prevalence of plasma cell-type pathology (47.8% vs. 4.6%, p < 0.001), and demonstrated a higher comorbidity index (2.48 vs. 1.14, p < 0.001) compared to UCD patients. MCD patients also had worse 5-year progression-free survival (81.6% vs. 100%, p < 0.001). Surgical UCD patients had better outcomes than non-surgical ones (p < 0.001). Multivariate analysis identified diabetes (HR = 9.9) and clinical subtype (HR = 15.8) as independent prognostic factors. VATS resulted in less bleeding (109 mL vs. 522 mL) and shorter hospital stays (4 vs. 7 days) than thoracotomy, though complication rates and long-term outcomes were similar. UCD and MCD exhibit distinct clinical and pathological profiles, necessitating different treatment approaches and resulting in varying prognoses. Individualized treatment plans should be tailored based on the type, location, and size of the lesion in each patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.